These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 30104712)

  • 1. Polo-like kinases and acute leukemia.
    Goroshchuk O; Kolosenko I; Vidarsdottir L; Azimi A; Palm-Apergi C
    Oncogene; 2019 Jan; 38(1):1-16. PubMed ID: 30104712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.
    Strebhardt K; Becker S; Matthess Y
    Expert Opin Drug Discov; 2015 Jan; 10(1):1-8. PubMed ID: 25263688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-mitotic functions of polo-like kinases in cancer cells.
    Raab CA; Raab M; Becker S; Strebhardt K
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
    Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
    Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of Plk3 in oncogenesis.
    Helmke C; Becker S; Strebhardt K
    Oncogene; 2016 Jan; 35(2):135-47. PubMed ID: 25915845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
    Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
    Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNAi prodrugs decrease elevated mRNA levels of Polo-like kinase 1 in ex vivo cultured primary cells from pediatric acute myeloid leukemia patients.
    Kolosenko I; Goroshchuk O; Vidarsdottir L; Björklund AC; Dowdy SF; Palm-Apergi C
    FASEB J; 2021 May; 35(5):e21476. PubMed ID: 33788972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Polo-like Kinase 1 as a Target for Anti-tumor Therapy].
    Procházková I; Vojtěšek B
    Klin Onkol; 2015; 28 Suppl 2():2S32-9. PubMed ID: 26374156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.
    Van den Bossche J; Lardon F; Deschoolmeester V; De Pauw I; Vermorken JB; Specenier P; Pauwels P; Peeters M; Wouters A
    Med Res Rev; 2016 Jul; 36(4):749-86. PubMed ID: 27140825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.
    Gutteridge RE; Ndiaye MA; Liu X; Ahmad N
    Mol Cancer Ther; 2016 Jul; 15(7):1427-35. PubMed ID: 27330107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.
    Zuco V; De Cesare M; Zaffaroni N; Lanzi C; Cassinelli G
    Oncotarget; 2015 Apr; 6(11):8736-49. PubMed ID: 25826089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies.
    Christoph DC; Schuler M
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):1115-30. PubMed ID: 21806334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress with polo-like kinase (PLK) inhibitors: a patent review (2018-present).
    Bian S; Zhang R; Nie J; Zhu M; Xie Z; Liao C; Wang Q
    Expert Opin Ther Pat; 2024 Sep; 34(9):789-806. PubMed ID: 38994687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
    Spartà AM; Bressanin D; Chiarini F; Lonetti A; Cappellini A; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Martelli AM
    Cell Cycle; 2014; 13(14):2237-47. PubMed ID: 24874015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children.
    Triscott J; Lee C; Foster C; Manoranjan B; Pambid MR; Berns R; Fotovati A; Venugopal C; O'Halloran K; Narendran A; Hawkins C; Ramaswamy V; Bouffet E; Taylor MD; Singhal A; Hukin J; Rassekh R; Yip S; Northcott P; Singh SK; Dunham C; Dunn SE
    Cancer Res; 2013 Nov; 73(22):6734-44. PubMed ID: 24019381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polo-like kinases in AML.
    Berg T; Bug G; Ottmann OG; Strebhardt K
    Expert Opin Investig Drugs; 2012 Aug; 21(8):1069-74. PubMed ID: 22667760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a high affinity selective inhibitor of Polo-like kinase 1 for cancer chemotherapy by computational approach.
    Kumar M; Pydi SP; Sharma S; Singh TP; Kaur P
    J Mol Graph Model; 2014 Jun; 51():104-12. PubMed ID: 24879322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Plk1 with siRNNs in primary cells from pediatric B-cell acute lymphoblastic leukemia patients.
    Goroshchuk O; Vidarsdottir L; Björklund AC; Hamil AS; Kolosenko I; Dowdy SF; Palm-Apergi C
    Sci Rep; 2020 Feb; 10(1):2688. PubMed ID: 32060361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies.
    Ikezoe T; Yang J; Nishioka C; Takezaki Y; Tasaka T; Togitani K; Koeffler HP; Yokoyama A
    Leukemia; 2009 Sep; 23(9):1564-76. PubMed ID: 19421227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.
    Valsasina B; Beria I; Alli C; Alzani R; Avanzi N; Ballinari D; Cappella P; Caruso M; Casolaro A; Ciavolella A; Cucchi U; De Ponti A; Felder E; Fiorentini F; Galvani A; Gianellini LM; Giorgini ML; Isacchi A; Lansen J; Pesenti E; Rizzi S; Rocchetti M; Sola F; Moll J
    Mol Cancer Ther; 2012 Apr; 11(4):1006-16. PubMed ID: 22319201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.